Navigation Links
Luminex Corporation Reports First Quarter 2013 Results
Date:4/29/2013

is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; our efforts to sell our molecular diagnostic products directly to end users; the development progress of our pipeline products, including Project Aries, NeoPlex4 and the NeoPlex System; anticipated FDA clearance of our products, including NeoPlex4 and the NeoPlex system and Project Aries; market acceptance of our products, including Gastrointestinal Pathogen Panel, Cystic Fibrosis, RVP FAST, 2D6 and other genetic testing products; our collaboration with Merck regarding an Alzheimer's diagnostic assay; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2013 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or
'/>"/>

SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Luminex Corporation Reports First Quarter 2012 Results
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Reports Second Quarter 2012 Results
5. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
6. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
7. Luminex Corporation Recognized as Best Technology Company in Austin
8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
9. Luminex Corporation To Present At Upcoming Investment Conferences In September
10. Luminex Corporation Reports Third Quarter 2012 Results
11. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Corporation (NYSE: CVS ) today announced that ... making a presentation to investors at the Citi Investment ... Mr. Merlo is scheduled to present at 2:10 pm ... webcast of the presentation will be broadcast simultaneously through ...
... NEW YORK, May 19, 2011 Two studies ... that an improved method for performing the standard upper endoscopy ... year increases the detection of pre-cancerous cells in the esophagus ... percent over the last 25 years, making it the fastest ...
Cached Medicine Technology:Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 2Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 3Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 4
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... 01, 2014 Currently, scientists continue ... treatments for Alzheimer's disease (AD), which reflects their ... regarding the diagnosis of the disease, especially in ... appropriate diagnostic tests. In 2014, after decades ... breakthroughs in the medicine world, there are still ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... who self-paid for their antiretroviral medications experienced interruptions ... or supply logistical disruptions. These treatment interruptions led ... in patients. ,These findings by a ... Institute at Makerere University, Kampala, and UCSF are ...
... 135-2 to pass (HB 1098) a Senate-approved bill that would ... until 2011, the New York Times reports.// ,Gov. ... that mandates that all girls entering the sixth grade beginning ... the executive order will allow parents who do not want ...
... least 3 years after undergoing in vitro fertilization (IVF) ... cell// research, according to a report. ,The ... of the report, was the complete and clear explanation ... legal advisor and embryologist, which helped couples navigate the ...
... Institute is seeking to raise glaucoma awareness among Mexican-Americans,// who ... Casa Grande Valley Dispatch reports. ,Mexican-Americans over ... family history of glaucoma all face a higher risk for ... the most common form glaucoma. ,The rate ...
... music and witty tales kept Delhi audiences enthralled as spiritual ... happiness and peace. ,Far from being a moral ... Thursday on 'Circus of the mind' was a simple talk ... is a very well-coordinated activity made to look like a ...
... The amount Americans spent on arthritis medications more than ... number of people// with the disease, increases in the ... inflation-adjusted cost per prescription, according to a new study ... a six-year study of U.S. arthritis patients and the ...
Cached Medicine News:Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Many Couples Choose to Donate Surplus Embryos for Stem Cell Research 2Health News:Mind Control is the Key to Happiness: Sadguru Jaggi Vasudev 2Health News:Treatment Cost for Arthritis on the Rise: Study 2
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
System, English (Continental cord), 230 VAC....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Medicine Products: